More recently, Peng et al. observed that approximately 82% of ITP patients with anti-GPIIbIIIa antibodies responded to IVIG therapy, while only 49% of the patients with anti-GPIbα antibodies were responsive [138]. The gene discussed is GP1BA; the disease is autoimmune thrombocytopenic purpura.